ArticleInternational journal of clinical oncology2026
Risk of second primary malignancies after bladder cancer diagnosed at a young age: a SEER population-based analysis.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBladder cancer diagnosed at a young age is uncommon, but survivors often have long life expectancy, making long-term risks such as second primary malignancies (SPMs) clinically relevant. However, the incidence and patterns of SPMs in young-onset bladder cancer survivors remain poorly characterized. We aimed to quantify the risk and distribution of SPMs in this population.
methodsWe conducted a retrospective cohort study using data from 17 registries in the Surveillance, Epidemiology, and End Results (SEER) program (2000-2022). Patients diagnosed with a first primary urothelial carcinoma of the bladder before age 50 were included. Follow-up for SPMs began two months after diagnosis. Standardized incidence ratios (SIRs) and absolute excess risks (AERs) were calculated overall, by sex, and by cancer site. Age-related trends were assessed using Poisson regression, and sensitivity analyses were performed.
resultsA total of 13,378 eligible patients contributed 140,014 person-years at risk to the SPM analysis. During follow-up, 1,272 SPMs were identified, excluding bladder and non-melanoma skin cancers, corresponding to a significantly elevated overall risk compared with the general U.S. population (SIR 1.67; 95% CI 1.58-1.76). Increased risk was observed in both men (SIR 1.81) and women (SIR 1.27). The largest elevations occurred for urinary tract malignancies outside the bladder, followed by colorectal, respiratory, renal cell carcinoma, and prostate cancers among men. No significant age-related trend was observed.
conclusionsYoung-onset bladder cancer survivors experience a sustained elevation in second primary malignancy risk, underscoring the importance of long-term survivorship awareness and informing counseling and follow-up strategies in this population.
Indexed as
Identifiers
42470523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.